PLCE1 and cancer: This reveals that PPL-C is an antagonistic mAb without antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which has the potential to be a therapeutic antibody drug for cancer.